Kalaris Therapeutics, Inc. 8-K Filing

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share KLRS The Nasdaq
• $10.00 — per share (the "Shares"), at a price of $10.00 per Share and, to certain Investors in
• $9.9999 — he "Pre-Funded Warrants") at a price of $9.9999 per Pre-Funded Warrant (the "Private Pl
• $50.0 m — the Private Placement of approximately $50.0 million, before deducting placement agent

Filing Documents

• d48530d8k.htm (8-K) — 42KB
• d48530dex41.htm (EX-4.1) — 74KB
• d48530dex101.htm (EX-10.1) — 207KB
• d48530dex102.htm (EX-10.2) — 90KB
• d48530dex991.htm (EX-99.1) — 11KB
• 0001193125-25-323706.txt ( ) — 653KB
• klrs-20251217.xsd (EX-101.SCH) — 3KB
• klrs-20251217_lab.xml (EX-101.LAB) — 18KB
• klrs-20251217_pre.xml (EX-101.PRE) — 11KB
• d48530d8k_htm.xml (XML) — 4KB

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risk and uncertainties. All statements, other than statements of historical fact, contained in this Current Report Form 8-K, including statements regarding the anticipated closing of the Private Placement; the anticipated proceeds from the Private Placement; the filing of a registration statement to register the resale of the Registrable Securities to be issued and sold in the Private Placement; the sufficiency of the Company's cash resources for the period anticipated; future expectations, plans and prospects for the Company, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are based on current expectations and beliefs of the management of the Company as well as assumptions made by, and information currently available to, the management of the Company and are subject to risks and uncertainties. There can be no assurance that future developments affecting the Company will be those that it has anticipated. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: risks associated with the clinical development and regulatory approval of TH103, including potential delays in the completion of clinical trials; expectations regarding the therapeutic benefits, clinical potential and clinical development of TH103; the timing of and the Company's abili

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 4.1 Form of Pre-Funded Warrant 10.1 Securities Purchase Agreement, dated December 17, 2025, by and among the Company and the Investor party thereto 10.2 Form of Registration Rights Agreement 99.1 Press Release, dated December 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALARIS THERAPEUTICS, INC. Date: December 18, 2025 By: /s/ Andrew Oxtoby Name: Andrew Oxtoby Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR